drugset / Trial / NCT00991458

Study of Cyclosporine in Post-LASIK Patients

NCT00991458

Phase 2 Completed 621 enrolled Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety and efficacy of Cyclosporine 0.005% and 0.010% eye drops administered twice daily before and following LASIK surgery.

Timeline

Start
2009-10
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 0.005 % Other
Subject Cyclosporine Peptide 0.01 % Other

Indications

No indication recorded.